Abstract
At a time when the twin epidemics of obesity and type 2 diabetes threaten to engulf even the most well-resourced Western healthcare systems, the nuclear receptor peroxisome proliferator-activated receptor
At a time when the twin epidemics of obesity and type 2 diabetes threaten to engulf even the most well-resourced Western healthcare systems, the nuclear receptor peroxisome proliferator-activated receptor
S. J. Olshansky, D. J. Passaro, and R. C. Hershow et al., “A potential decline in life expectancy in the United States in the 21st century,” New England Journal of Medicine, vol. 352, no. 11, pp. 1138–1145, 2005.
View at: Publisher Site | Google ScholarC. L. Ogden, M. D. Carroll, L. R. Curtin, M. A. McDowell, C. J. Tabak, and K. M. Flegal, “Prevalence of overweight and obesity in the United States, 1999–2004,” Journal of the American Medical Association, vol. 295, no. 13, pp. 1549–1555, 2006.
View at: Publisher Site | Google ScholarR. H. Eckel, S. M. Grundy, and P. Z. Zimmet, “The metabolic syndrome,” The Lancet, vol. 365, no. 9468, pp. 1415–1428, 2005.
View at: Publisher Site | Google ScholarJ. Tuomilehto, J. Lindström, and J. G. Eriksson et al., “Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance,” New England Journal of Medicine, vol. 344, no. 18, pp. 1343–1350, 2001.
View at: Publisher Site | Google ScholarW. C. Knowler, E. Barrett-Connor, and S. E. Fowler et al., “Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin,” New England Journal of Medicine, vol. 346, no. 6, pp. 393–403, 2002.
View at: Publisher Site | Google ScholarJ. Auwerx, “PPAR, the ultimate thrifty gene,” Diabetologia, vol. 42, no. 9, pp. 1033–1049, 1999.
View at: Publisher Site | Google ScholarB. M. Forman, J. Chen, and R. M. Evans, “The peroxisome proliferator-activated receptors: ligands and activators,” Annals of the New York Academy of Sciences, vol. 804, pp. 266–275, 1996.
View at: Publisher Site | Google ScholarH. Yki-Järvinen, “Thiazolidinediones,” New England Journal of Medicine, vol. 351, no. 11, pp. 1106–1118, 2004.
View at: Publisher Site | Google ScholarJ. A. Dormandy, B. Charbonnel, and D. J. Eckland et al., “Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macro vascular events): a randomised controlled trial,” The Lancet, vol. 366, no. 9493, pp. 1279–1289, 2005.
View at: Publisher Site | Google ScholarDREAM trial investigators, “Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial,” The Lancet, vol. 368, no. 9541, pp. 1096–1105, 2006.
View at: Publisher Site | Google ScholarJ. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer, “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor (PPAR),” Journal of Biological Chemistry, vol. 270, no. 22, pp. 12953–12956, 1995.
View at: Publisher Site | Google ScholarV. Fonseca, “Effect of thiazolidinediones on body weight in patients with diabetes mellitus,” American Journal of Medicine, vol. 115, no. 8, supplement 1, pp. 42–48, 2003.
View at: Publisher Site | Google ScholarT. M. Larsen, S. Toubro, and A. Astrup, “PPAR agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy?,” International Journal of Obesity, vol. 27, no. 2, pp. 147–161, 2003.
View at: Publisher Site | Google ScholarY. Guan, C. Hao, and D. R. Cha et al., “Thiazolidinediones expand body fluid volume through PPAR stimulation of ENaC-mediated renal salt absorption,” Nature Medicine, vol. 11, no. 8, pp. 861–866, 2005.
View at: Publisher Site | Google ScholarS. Mudaliar, A. R. Chang, and R. R. Henry, “Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications,” Endocrine Practice, vol. 9, no. 5, pp. 406–416, 2003.
View at: Google ScholarI. Barroso, M. Gurnell, and V. E. F. Crowley et al., “Dominant negative mutations in human PPAR associated with severe insulin resistance, diabetes mellitus and hypertension,” Nature, vol. 402, no. 6764, pp. 880–883, 1999.
View at: Publisher Site | Google ScholarA. K. Agarwal and A. Garg, “A novel heterozygous mutation in peroxisome proliferator-activated receptor- gene in a patient with familial partial lipodystrophy,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 1, pp. 408–411, 2002.
View at: Publisher Site | Google ScholarR. A. Hegele, H. Cao, C. Frankowski, S. T. Mathews, and T. Leff, “PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy,” Diabetes, vol. 51, no. 12, pp. 3586–3590, 2002.
View at: Google ScholarD. B. Savage, G. D. Tan, and C. L. Acerini et al., “Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-,” Diabetes, vol. 52, no. 4, pp. 910–917, 2003.
View at: Google ScholarD. B. Savage, M. Agostini, and I. Barroso et al., “Digenic inheritance of severe insulin resistance in a human pedigree,” Nature Genetics, vol. 31, no. 4, pp. 379–384, 2002.
View at: Publisher Site | Google ScholarG. A. Francis, G. Li, and R. Casey et al., “Peroxisomal proliferator activated receptor- deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3),” BMC Medical Genetics, vol. 7, p. 3, 2006.
View at: Publisher Site | Google ScholarR. A. Hegele, E. Ur, T. P. Ransom, and H. Cao, “A frameshift mutation in peroxisome-proliferator-activated receptor- in familial partial lipodystrophy subtype 3 (FPLD3; MIM 604367),” Clinical Genetics, vol. 70, no. 4, pp. 360–362, 2006.
View at: Publisher Site | Google ScholarM. Agostini, E. Schoenmakers, and C. Mitchell et al., “Non-DNA binding, dominant-negative, human PPAR mutations cause lipodystrophic insulin resistance,” Cell Metabolism, vol. 4, no. 4, pp. 303–311, 2006.
View at: Publisher Site | Google ScholarH.-P. Guan, T. Ishizuka, P. C. Chui, M. Lehrke, and M. A. Lazar, “Corepressors selectively control the transcriptional activity of PPAR in adipocytes,” Genes and Development, vol. 19, no. 4, pp. 453–461, 2005.
View at: Publisher Site | Google ScholarR. M. Evans, G. D. Barish, and Y.-X. Wang, “PPARs and the complex journey to obesity,” Nature Medicine, vol. 10, no. 4, pp. 355–361, 2004.
View at: Publisher Site | Google ScholarG. D. Barish, V. A. Narkar, and R. M. Evans, “PPAR: a dagger in the heart of the metabolic syndrome,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 590–597, 2006.
View at: Publisher Site | Google ScholarL. Fajas, D. Auboeuf, and E. Raspé et al., “The organization, promoter analysis, and expression of the human PPAR gene,” Journal of Biological Chemistry, vol. 272, no. 30, pp. 18779–18789, 1997.
View at: Publisher Site | Google ScholarL. Fajas, J.-C. Fruchart, and J. Auwerx, “PPAR3 mRNA: a distinct PPAR mRNA subtype transcribed from an independent promoter,” FEBS Letters, vol. 438, no. 1-2, pp. 55–60, 1998.
View at: Publisher Site | Google ScholarH. Sundvold and S. Lien, “Identification of a novel peroxisome proliferator-activated receptor (PPAR) promoter in man and transactivation by the nuclear receptor ROR1,” Biochemical and Biophysical Research Communications, vol. 287, no. 2, pp. 383–390, 2001.
View at: Publisher Site | Google ScholarB. Desvergne and W. Wahli, “Peroxisome proliferator-activated receptors: nuclear control of metabolism,” Endocrine Reviews, vol. 20, no. 5, pp. 649–688, 1999.
View at: Publisher Site | Google ScholarI. Tzameli, H. Fang, and M. Ollero et al., “Regulated production of a peroxisome proliferator-activated receptor- ligand during an early phase of adipocyte differentiation in 3T3-L1 adipocytes,” Journal of Biological Chemistry, vol. 279, no. 34, pp. 36093–36102, 2004.
View at: Publisher Site | Google ScholarE. D. Rosen, C.-H. Hsu, and X. Wang et al., “C/EBP induces adipogenesis through PPAR: a unified pathway,” Genes and Development, vol. 16, no. 1, pp. 22–26, 2002.
View at: Publisher Site | Google ScholarP. Tontonoz, E. Hu, and B. M. Spiegelman, “Stimulation of adipogenesis in fibroblasts by PPAR2, a lipid-activated transcription factor,” Cell, vol. 79, no. 7, pp. 1147–1156, 1994.
View at: Publisher Site | Google ScholarY. Barak, M. C. Nelson, and E. S. Ong et al., “PPAR is required for placental, cardiac, and adipose tissue development,” Molecular Cell, vol. 4, no. 4, pp. 585–595, 1999.
View at: Publisher Site | Google ScholarE. D. Rosen, P. Sarraf, and A. E. Troy et al., “PPAR is required for the differentiation of adipose tissue in vivo and in vitro,” Molecular Cell, vol. 4, no. 4, pp. 611–617, 1999.
View at: Publisher Site | Google ScholarN. Kubota, Y. Terauchi, and H. Miki et al., “PPAR mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance,” Molecular Cell, vol. 4, no. 4, pp. 597–609, 1999.
View at: Publisher Site | Google ScholarM. Gurnell, J. M. Wentworth, and M. Agostini et al., “A dominant-negative peroxisome proliferator-activated receptor (PPAR) mutant is a constitutive repressor and inhibits PPAR-mediated adipogenesis,” Journal of Biological Chemistry, vol. 275, no. 8, pp. 5754–5759, 2000.
View at: Publisher Site | Google ScholarH. Bays, L. Mandarino, and R. A. DeFronzo, “Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 2, pp. 463–478, 2004.
View at: Publisher Site | Google ScholarM. Adams, C. T. Montague, and J. B. Prins et al., “Activators of peroxisome proliferator-activated receptor have depot-specific effects on human preadipocyte differentiation,” Journal of Clinical Investigation, vol. 100, no. 12, pp. 3149–3153, 1997.
View at: Google ScholarM. Ristow, D. Müller-Wieland, A. Pfeiffer, W. Krone, and C. R. Kahn, “Obesity associated with a mutation in a genetic regulator of adipocyte differentiation,” New England Journal of Medicine, vol. 339, no. 14, pp. 953–959, 1998.
View at: Publisher Site | Google ScholarE. Hu, J. B. Kim, P. Sarraf, and B. M. Spiegelman, “Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPAR,” Science, vol. 274, no. 5295, pp. 2100–2103, 1996.
View at: Publisher Site | Google ScholarM. Adams, M. J. Reginato, D. Shao, M. A. Lazar, and V. K. Chatterjee, “Transcriptional activation by peroxisome proliferator-activated receptor is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site,” Journal of Biological Chemistry, vol. 272, no. 8, pp. 5128–5132, 1997.
View at: Publisher Site | Google ScholarM. Blüher and R. Paschke, “Analysis of the relationship between PPAR- 2 gene variants and severe insulin resistance in obese patients with impaired glucose tolerance,” Experimental and Clinical Endocrinology and Diabetes, vol. 111, no. 2, pp. 85–90, 2003.
View at: Google ScholarM. Agostini, M. Gurnell, and D. B. Savage et al., “Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor ,” Endocrinology, vol. 145, no. 4, pp. 1527–1538, 2004.
View at: Publisher Site | Google ScholarK. Al-Shali, H. Cao, N. Knoers, A. R. Hermus, C. J. Tack, and R. A. Hegele, “A single-base mutation in the peroxisome proliferator-activated receptor 4 promoter associated with altered in vitro expression and partial lipodystrophy,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 11, pp. 5655–5660, 2004.
View at: Publisher Site | Google ScholarY.-S. Tsai, H.-J. Kim, and N. Takahashi et al., “Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPAR,” Journal of Clinical Investigation, vol. 114, no. 2, pp. 240–249, 2004.
View at: Google ScholarS. L. Gray, E. D. Nora, and J. Grosse et al., “Leptin deficiency unmasks the deleterious effects of impaired peroxisome proliferator-activated receptor function (P465L PPAR) in mice,” Diabetes, vol. 55, no. 10, pp. 2669–2677, 2006.
View at: Publisher Site | Google ScholarS. S. Deeb, L. Fajas, and M. Nemoto et al., “A Pro12Ala substitution in PPAR2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity,” Nature Genetics, vol. 20, no. 3, pp. 284–287, 1998.
View at: Publisher Site | Google ScholarM. Stumvoll and H. Häring, “The peroxisome proliferator-activated receptor-2 Pro12Ala polymorphism,” Diabetes, vol. 51, no. 8, pp. 2341–2347, 2002.
View at: Google ScholarM. M. Swarbrick, C. M. L. Chapman, B. M. McQuillan, J. Hung, P. L. Thompson, and J. P. Beilby, “A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor-2 is associated with combined hyperlipidaemia in obesity,” European Journal of Endocrinology, vol. 144, no. 3, pp. 277–282, 2001.
View at: Publisher Site | Google ScholarB. A. Beamer, C.-J. Yen, and R. E. Andersen et al., “Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-2 gene with obesity in two Caucasian populations,” Diabetes, vol. 47, no. 11, pp. 1806–1808, 1998.
View at: Google ScholarS. Masud and S. Ye, “Effect of the peroxisome proliferates activated receptor- gene Pro12Ala variant on body mass index: a meta-analysis,” Journal of Medical Genetics, vol. 40, no. 10, pp. 773–780, 2003.
View at: Publisher Site | Google ScholarJ. Luan, P. O. Browne, and A.-H. Harding et al., “Evidence for gene-nutrient interaction at the PPAR locus,” Diabetes, vol. 50, no. 3, pp. 686–689, 2001.
View at: Google ScholarJ. Robitaille, J.-P. Després, L. Pérusse, and M.-C. Vohl, “The PPAR- P12A polymorphism modulates the relationship between dietary fat intake and components of the metabolic syndrome: results from the Québec family study,” Clinical Genetics, vol. 63, no. 2, pp. 109–116, 2003.
View at: Publisher Site | Google ScholarT. M. Willson, J. E. Cobb, and D. J. Cowan et al., “The structure—activity relationship between peroxisome proliferator-activated receptor agonism and the antihyperglycemic activity of thiazolidinediones,” Journal of Medicinal Chemistry, vol. 39, no. 3, pp. 665–668, 1996.
View at: Publisher Site | Google ScholarR. Mukherjee, P. J. A. Davies, and D. L. Crombie et al., “Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists,” Nature, vol. 386, no. 6623, pp. 407–410, 1997.
View at: Publisher Site | Google ScholarS. M. Rangwala, B. Rhoades, and J. S. Shapiro et al., “Genetic modulation of PPAR phosphorylation regulates insulin sensitivity,” Developmental Cell, vol. 5, no. 4, pp. 657–663, 2003.
View at: Publisher Site | Google ScholarW. He, Y. Barak, and A. Hevener et al., “Adipose-specific peroxisome proliferator-activated receptor knockout causes insulin resistance in fat and liver but not in muscle,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 26, pp. 15712–15717, 2003.
View at: Publisher Site | Google ScholarA. L. Hevener, W. He, and Y. Barak et al., “Muscle-specific Pparg deletion causes insulin resistance,” Nature Medicine, vol. 9, no. 12, pp. 1491–1497, 2003.
View at: Publisher Site | Google ScholarA. W. Norris, L. Chen, and S. J. Fisher et al., “Muscle-specific PPAR-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones,” Journal of Clinical Investigation, vol. 112, no. 4, pp. 608–618, 2003.
View at: Publisher Site | Google ScholarK. Matsusue, M. Haluzik, and G. Lambert et al., “Liver-specific disruption of PPAR in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes,” Journal of Clinical Investigation, vol. 111, no. 5, pp. 737–747, 2003.
View at: Publisher Site | Google ScholarJ. C. Florez, J. Hirschhorn, and D. Altshuler, “The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits,” Annual Review of Genomics and Human Genetics, vol. 4, pp. 257–291, 2003.
View at: Publisher Site | Google ScholarA. Memisoglu, F. B. Hu, and S. E. Hankinson et al., “Prospective study of the association between the proline to alanine codon 12 polymorphism in the PPAR gene and type 2 diabetes,” Diabetes Care, vol. 26, no. 10, pp. 2915–2917, 2003.
View at: Google ScholarE. S. Tai, D. Corella, and M. Deurenberg-Yap et al., “Differential effects of the C1431T and Pro12Ala PPAR gene variants on plasma lipids and diabetes risk in an Asian population,” Journal of Lipid Research, vol. 45, no. 4, pp. 674–685, 2004.
View at: Publisher Site | Google ScholarA. S. F. Doney, B. Fischer, and J. E. Cecil et al., “Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to type 2 diabetes,” Diabetologia, vol. 47, no. 3, pp. 555–558, 2004.
View at: Publisher Site | Google ScholarL. Chao, B. Marcus-Samuels, and M. M. Mason et al., “Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones,” Journal of Clinical Investigation, vol. 106, no. 10, pp. 1221–1228, 2000.
View at: Google ScholarK. Schoonjans, J. Peinado-Onsurbe, and A.-M. Lefebvre et al., “PPAR and PPAR activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene,” EMBO Journal, vol. 15, no. 19, pp. 5336–5348, 1996.
View at: Google ScholarB. I. Frohnert, T. Y. Hui, and D. A. Bernlohr, “Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene,” Journal of Biological Chemistry, vol. 274, no. 7, pp. 3970–3977, 1999.
View at: Publisher Site | Google ScholarH.-P. Guan, Y. Li, M. V. Jensen, C. B. Newgard, C. M. Steppan, and M. A. Lazar, “A futile metabolic cycle activated in adipocytes by antidiabetic agents,” Nature Medicine, vol. 8, no. 10, pp. 1122–1128, 2002.
View at: Publisher Site | Google ScholarJ. Tordjman, G. Chauvet, J. Quette, E. G. Beale, C. Forest, and B. Antoine, “Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells,” Journal of Biological Chemistry, vol. 278, no. 21, pp. 18785–18790, 2003.
View at: Publisher Site | Google ScholarO. Vaccaro, F. P. Mancini, and G. Ruffa et al., “Fasting plasma free fatty acid concentrations and Pro12Ala polymorphism of the peroxisome proliferator-activated receptor (PPAR) 2 gene in healthy individuals,” Clinical Endocrinology, vol. 57, no. 4, pp. 481–486, 2002.
View at: Publisher Site | Google ScholarP. Peraldi, M. Xu, and B. M. Spiegelman, “Thiazolidinediones block tumor necrosis factor--induced inhibition of insulin signaling,” Journal of Clinical Investigation, vol. 100, no. 7, pp. 1863–1869, 1997.
View at: Google ScholarC. M. Steppan, S. T. Bailey, and S. Bhat et al., “The hormone resistin links obesity to diabetes,” Nature, vol. 409, no. 6818, pp. 307–312, 2001.
View at: Publisher Site | Google ScholarQ. Yang, T. E. Graham, and N. Mody et al., “Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes,” Nature, vol. 436, no. 7049, pp. 356–362, 2005.
View at: Publisher Site | Google ScholarN. Maeda, M. Takahashi, and T. Funahashi et al., “PPAR ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein,” Diabetes, vol. 50, no. 9, pp. 2094–2099, 2001.
View at: Google ScholarR. S. Ahima and J. S. Flier, “Adipose tissue as an endocrine organ,” Trends in Endocrinology and Metabolism, vol. 11, no. 8, pp. 327–332, 2000.
View at: Publisher Site | Google ScholarT. P. Combs, J. A. Wagner, and J. Berger et al., “Induction of adipocyte complement-related protein of 30 kilodaltons by PPAR agonists: a potential mechanism of insulin sensitization,” Endocrinology, vol. 143, no. 3, pp. 998–1007, 2002.
View at: Publisher Site | Google ScholarR. K. Semple, M. A. Soos, and J. Luan et al., “Elevated plasma adiponectin in humans with genetically defective insulin receptors,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 8, pp. 3219–3223, 2006.
View at: Publisher Site | Google ScholarM. Iwata, T. Haruta, and I. Usui et al., “Pioglitazone ameliorates tumor necrosis factor--induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator-activated receptor-,” Diabetes, vol. 50, no. 5, pp. 1083–1092, 2001.
View at: Google ScholarU. Smith, S. Gogg, A. Johansson, T. Olausson, V. Rotter, and B. Svalstedt, “Thiazolidinediones (PPAR agonists) but not PPAR agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes,” FASEB Journal, vol. 15, no. 1, pp. 215–220, 2001.
View at: Publisher Site | Google ScholarJ. Rieusset, C. Chambrier, and K. Bouzakri et al., “The expression of the p85 subunit of phosphatidylinositol 3-kinase is induced by activation of the peroxisome proliferator-activated receptor in human adipocytes,” Diabetologia, vol. 44, no. 5, pp. 544–554, 2001.
View at: Publisher Site | Google ScholarV. Ribon, J. H. Johnson, H. S. Camp, and A. R. Saltiel, “Thiazolidinediones and insulin resistance: peroxisome proliferator-activated receptor activation stimulates expression of the CAP gene,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 25, pp. 14751–14756, 1998.
View at: Publisher Site | Google ScholarC. A. Baumann, N. Chokshi, A. R. Saltiel, and V. Ribon, “Cloning and characterization of a functional peroxisome proliferator activator receptor--responsive element in the promoter of the CAP gene,” Journal of Biological Chemistry, vol. 275, no. 13, pp. 9131–9135, 2000.
View at: Publisher Site | Google ScholarI. J. Bujalska, S. Kumar, and P. M. Stewart, “Does central obesity reflect “Cushing's disease of the omentum”?,” The Lancet, vol. 349, no. 9060, pp. 1210–1213, 1997.
View at: Publisher Site | Google ScholarH. Masuzaki, J. Paterson, and H. Shinyama et al., “A transgenic model of visceral obesity and the metabolic syndrome,” Science, vol. 294, no. 5549, pp. 2166–2170, 2001.
View at: Publisher Site | Google ScholarJ. Berger, M. Tanen, and A. Elbrecht et al., “Peroxisome proliferator-activated receptor- ligands inhibit adipocyte -hydroxysteroid dehydrogenase type 1 expression and activity,” Journal of Biological Chemistry, vol. 276, no. 16, pp. 12629–12635, 2001.
View at: Publisher Site | Google ScholarB. S. Cha, T. P. Ciaraldi, and L. Carter et al., “Peroxisome proliferator-activated receptor (PPAR) and retinoid X receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle,” Diabetologia, vol. 44, no. 4, pp. 444–452, 2001.
View at: Publisher Site | Google ScholarC. Kausch, J. Krützfeldt, and A. Witke et al., “Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscle cells,” Biochemical and Biophysical Research Communications, vol. 280, no. 3, pp. 664–674, 2001.
View at: Publisher Site | Google ScholarA. A. Parulkar, M. L. Pendergrass, R. Granda-Ayala, T. R. Lee, and V. A. Fonseca, “Nonhypoglycemic effects of thiazolidinediones,” Annals of Internal Medicine, vol. 134, no. 1, pp. 61–71, 2001.
View at: Google ScholarF. Massiéra, M. Bloch-Faure, and D. Ceiler et al., “Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation,” The FASEB Journal, vol. 15, no. 14, pp. 2727–2729, 2001.
View at: Publisher Site | Google ScholarC. J. Östgren, U. Lindblad, O. Melander, A. Melander, L. Groop, and L. Rȧstam, “Peroxisome proliferator-activated receptor-Pro12Ala polymorphism and the association with blood pressure in type 2 diabetes: skaraborg hypertension and diabetes project,” Journal of Hypertension, vol. 21, no. 9, pp. 1657–1662, 2003.
View at: Google ScholarS. J. Hasstedt, Q.-F. Ren, K. Teng, and S. C. Elbein, “Effect of the peroxisome proliferator-activated receptor-2 Pro12Ala variant on obesity, glucose homeostasis, and blood pressure in members of familial type 2 diabetic kindreds,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 2, pp. 536–541, 2001.
View at: Publisher Site | Google ScholarB. Isomaa, P. Almgren, and T. Toumi et al., “Cardiovascular morbidity and mortality associated with the metabolic syndrome,” Diabetes Care, vol. 24, no. 4, pp. 683–689, 2001.
View at: Google ScholarJ. Minamikawa, S. Tanaka, M. Yamauchi, D. Inoue, and H. Koshiyama, “Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes,” Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 5, pp. 1818–1820, 1998.
View at: Publisher Site | Google ScholarP. Tontonoz, L. Nagy, J. G. A. Alvarez, V. A. Thomazy, and R. M. Evans, “PPAR promotes monocyte/macrophage differentiation and uptake of oxidized LDL,” Cell, vol. 93, no. 2, pp. 241–252, 1998.
View at: Publisher Site | Google ScholarL. Nagy, P. Tontonoz, J. G. A. Alvarez, H. Chen, and R. M. Evans, “Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR,” Cell, vol. 93, no. 2, pp. 229–240, 1998.
View at: Publisher Site | Google ScholarM. Ricote, J. Huang, and L. Fajas et al., “Expression of the peroxisome proliferator-activated receptor (PPAR) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 13, pp. 7614–7619, 1998.
View at: Publisher Site | Google ScholarC. Jiang, A. T. Ting, and B. Seed, “PPAR- agonists inhibit production of monocyte inflammatory cytokines,” Nature, vol. 391, no. 6662, pp. 82–86, 1998.
View at: Publisher Site | Google ScholarM. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor- is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998.
View at: Publisher Site | Google ScholarJ. S. Welch, M. Ricote, T. E. Akiyama, F. J. Gonzalez, and C. K. Glass, “PPAR and PPAR negatively regulate specific subsets of lipopolysaccharide and IFN- target genes in macrophages,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 11, pp. 6712–6717, 2003.
View at: Publisher Site | Google ScholarK. J. Moore, E. D. Rosen, and M. L. Fitzgerald et al., “The role of PPAR- in macrophage differentiation and cholesterol uptake,” Nature Medicine, vol. 7, no. 1, pp. 41–47, 2001.
View at: Publisher Site | Google ScholarA. R. Tall, P. Costet, and N. Wang, “Regulation and mechanisms of macrophage cholesterol efflux,” Journal of Clinical Investigation, vol. 110, no. 7, pp. 899–904, 2002.
View at: Publisher Site | Google ScholarG. Chinetti, S. Lestavel, and V. Bocher et al., “PPAR- and PPAR- activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway,” Nature Medicine, vol. 7, no. 1, pp. 53–58, 2001.
View at: Publisher Site | Google ScholarA. Chawla, Y. Barak, L. Nagy, D. Liao, P. Tontonoz, and R. M. Evans, “PPAR- dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation,” Nature Medicine, vol. 7, no. 1, pp. 48–52, 2001.
View at: Publisher Site | Google ScholarE. Iwata, I. Yamamoto, and T. Motomura et al., “The association of Pro12Ala polymorphism in PPAR2 with lower carotid artery IMT in Japanese,” Diabetes Research and Clinical Practice, vol. 62, no. 1, pp. 55–59, 2003.
View at: Publisher Site | Google ScholarZ. C. Yan, Z. M. Zhu, and C. Y. Shen et al., “Peroxisome proliferator-activated receptor C-161T polymorphism and carotid artery atherosclerosis in metabolic syndrome,” Zhonghua Yi Xue Za Zhi, vol. 84, no. 7, pp. 543–547, 2004 (Chinese).
View at: Google ScholarY. Li and M. A. Lazar, “Differential gene regulation by PPAR agonist and constitutively active PPAR2,” Molecular Endocrinology, vol. 16, no. 5, pp. 1040–1048, 2002.
View at: Publisher Site | Google ScholarM. J. Reginato, S. T. Bailey, and S. L. Krakow et al., “A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor -activating properties,” Journal of Biological Chemistry, vol. 273, no. 49, pp. 32679–32684, 1998.
View at: Publisher Site | Google ScholarS. Rocchi, F. Picard, and J. Vamecq et al., “A unique PPAR ligand with potent insulin-sensitizing yet weak adipogenic activity,” Molecular Cell, vol. 8, no. 4, pp. 737–747, 2001.
View at: Publisher Site | Google ScholarA. Shimaya, E. Kurosaki, R. Nakano, R. Hirayama, M. Shibasaki, and H. Shikama, “The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice,” Metabolism: Clinical and Experimental, vol. 49, no. 3, pp. 411–417, 2000.
View at: Google ScholarP. Misra, R. Chakrabarti, and R. K. Vikramadithyan et al., “PAT5A: a partial agonist of peroxisome proliferator-activated receptor is a potent antidiabetic thiazolidinedione yet weakly adipogenic,” Journal of Pharmacology and Experimental Therapeutics, vol. 306, no. 2, pp. 763–771, 2003.
View at: Publisher Site | Google ScholarJ. P. Berger, A. E. Petro, and K. L. MacNaul et al., “Distinct properties and advantages of a novel peroxisome proliferator-activated protein selective modulator,” Molecular Endocrinology, vol. 17, no. 4, pp. 662–676, 2003.
View at: Publisher Site | Google ScholarK. R. Kim, J. H. Lee, and S. J. Kim et al., “KR-62980: a novel peroxisome proliferator-activated receptor agonist with weak adipogenic effects,” Biochemical Pharmacology, vol. 72, no. 4, pp. 446–454, 2006.
View at: Publisher Site | Google ScholarK. Liu, R. M. Black, and J. J. Acton III et al., “Selective PPAR modulators with improved pharmacological profiles,” Bioorganic and Medicinal Chemistry Letters, vol. 15, no. 10, pp. 2437–2440, 2005.
View at: Publisher Site | Google Scholar